PDCD1 and cancer: In terms of DFS, the cancer PD1+ and TIL PD1+ patients both demonstrated a significantly reduced DFS (5-year DFS of 71.3 vs. 41.6%; log-rank 0.008 and 73.3 vs. 41.9%; log-rank 0.008, respectively; Table 3).